The blog
Clinical trial results, TGA regulatory progress and research updates on retatrutide and the wider peptide space — explained for Australians.
13 September 2026 · tb-500 · thymosin-beta-4 · peptides · clinical-trials · australia
Thymosin beta-4's first randomised heart attack trial missed its overall endpoint. What that means for TB-500 research and its legal status in Australia.
Read more →10 September 2026 · tb-500 · thymosin-beta-4 · peptide-regulation · tga · fda
Is TB-500 legal in Australia? What the vial contains often isn't thymosin beta-4 - and a July 2026 FDA panel vote made the distinction impossible to ignore.
Read more →28 August 2026 · tb-500 · thymosin-beta-4 · peptides · australia · research
TB-500 is sold for injury recovery, but thymosin beta-4's only late-stage human trials are eye drops. What the 2026 evidence and Australian rules say.
Read more →27 August 2026 · tb-500 · peptides · recovery · research
TB-500 is sold as a recovery peptide, but the thymosin beta-4 evidence is mostly animal research. What the science, WADA and the TGA actually say.
Read more →Stay informed
Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:
Get the free guide + updates
Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.